Cargando…
IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant
Recombinant trimeric SARS-CoV-2 Spike protein with PIKA (polyI:C) adjuvant induces potent and durable neutralizing antibodies that protect against multiple SARS-CoV-2 variants. The immunoglobulin subclasses of viral-specific antibodies remain unknown, as do their glycosylation status on Fc regions....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144704/ https://www.ncbi.nlm.nih.gov/pubmed/37112739 http://dx.doi.org/10.3390/vaccines11040827 |
_version_ | 1785034160057876480 |
---|---|
author | Wang, Jingxia Mai, Xinjia He, Yu Zhu, Chenxi Zhou, Dapeng |
author_facet | Wang, Jingxia Mai, Xinjia He, Yu Zhu, Chenxi Zhou, Dapeng |
author_sort | Wang, Jingxia |
collection | PubMed |
description | Recombinant trimeric SARS-CoV-2 Spike protein with PIKA (polyI:C) adjuvant induces potent and durable neutralizing antibodies that protect against multiple SARS-CoV-2 variants. The immunoglobulin subclasses of viral-specific antibodies remain unknown, as do their glycosylation status on Fc regions. In this study, we analyzed immunoglobulins adsorbed by plate-bound recombinant trimeric SARS-CoV-2 Spike protein from serum of Cynomolgus monkey immunized by recombinant trimeric SARS-CoV-2 Spike protein with PIKA (polyI:C) adjuvant. The results showed that IgG1 was the dominant IgG subclass as revealed by ion mobility mass spectrometry. The average percentage of Spike protein-specific IgG1 increased to 88.3% as compared to pre-immunization. Core fucosylation for Fc glycopeptide of Spike protein-specific IgG1 was found to be higher than 98%. These results indicate that a unique Th1-biased, IgG1-dominant antibody response was responsible for the effectiveness of PIKA (polyI:C) adjuvant. Vaccine-induced core-fucosylation of IgG1 Fc region may reduce incidence of severe COVID-19 disease associated with overstimulation of FCGR3A by afucosylated IgG1. |
format | Online Article Text |
id | pubmed-10144704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101447042023-04-29 IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant Wang, Jingxia Mai, Xinjia He, Yu Zhu, Chenxi Zhou, Dapeng Vaccines (Basel) Brief Report Recombinant trimeric SARS-CoV-2 Spike protein with PIKA (polyI:C) adjuvant induces potent and durable neutralizing antibodies that protect against multiple SARS-CoV-2 variants. The immunoglobulin subclasses of viral-specific antibodies remain unknown, as do their glycosylation status on Fc regions. In this study, we analyzed immunoglobulins adsorbed by plate-bound recombinant trimeric SARS-CoV-2 Spike protein from serum of Cynomolgus monkey immunized by recombinant trimeric SARS-CoV-2 Spike protein with PIKA (polyI:C) adjuvant. The results showed that IgG1 was the dominant IgG subclass as revealed by ion mobility mass spectrometry. The average percentage of Spike protein-specific IgG1 increased to 88.3% as compared to pre-immunization. Core fucosylation for Fc glycopeptide of Spike protein-specific IgG1 was found to be higher than 98%. These results indicate that a unique Th1-biased, IgG1-dominant antibody response was responsible for the effectiveness of PIKA (polyI:C) adjuvant. Vaccine-induced core-fucosylation of IgG1 Fc region may reduce incidence of severe COVID-19 disease associated with overstimulation of FCGR3A by afucosylated IgG1. MDPI 2023-04-11 /pmc/articles/PMC10144704/ /pubmed/37112739 http://dx.doi.org/10.3390/vaccines11040827 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Wang, Jingxia Mai, Xinjia He, Yu Zhu, Chenxi Zhou, Dapeng IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant |
title | IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant |
title_full | IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant |
title_fullStr | IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant |
title_full_unstemmed | IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant |
title_short | IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant |
title_sort | igg1-dominant antibody response induced by recombinant trimeric sars-cov-2 spike protein with pika adjuvant |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144704/ https://www.ncbi.nlm.nih.gov/pubmed/37112739 http://dx.doi.org/10.3390/vaccines11040827 |
work_keys_str_mv | AT wangjingxia igg1dominantantibodyresponseinducedbyrecombinanttrimericsarscov2spikeproteinwithpikaadjuvant AT maixinjia igg1dominantantibodyresponseinducedbyrecombinanttrimericsarscov2spikeproteinwithpikaadjuvant AT heyu igg1dominantantibodyresponseinducedbyrecombinanttrimericsarscov2spikeproteinwithpikaadjuvant AT zhuchenxi igg1dominantantibodyresponseinducedbyrecombinanttrimericsarscov2spikeproteinwithpikaadjuvant AT zhoudapeng igg1dominantantibodyresponseinducedbyrecombinanttrimericsarscov2spikeproteinwithpikaadjuvant |